Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
REGULATORY Japan Panel Backs Approval of Takeda’s Acquired Hemophilia A Drug
February 26, 2024
-
BUSINESS Novel Antibiotic Fetroja Approved in Taiwan: Shionogi
February 26, 2024
-
BUSINESS Maruho’s China Subsidiary Now Up and Running
February 26, 2024
-
BUSINESS Economic Terms for Obesity Drug Deal Disclosed by Lilly: Chugai
February 26, 2024
-
BUSINESS As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
-
REGULATORY Drug Comparisons in Promotional Activities Allowed under 4 Conditions: MHLW
February 26, 2024
-
REGULATORY Deduction Formula for IP Box Tax Relief Now Clear as Preparations Move Ahead
February 22, 2024
-
REGULATORY LDP Panel OKs Bill to Amend Regenerative Medicine Safety Act, but Lawmakers Fret Lack of Ban on “Designer Babies”
February 22, 2024
-
REGULATORY Japan to Revisit Vaccine Lot Release Process to Eradicate Double Testing
February 22, 2024
-
COLUMN Positioning Your Company as an Employer of Choice
February 22, 2024
-
REGULATORY New Doctor Payment Disclosure Rule to Apply to Foreign Firms with Japan Subsidiaries
February 21, 2024
-
BUSINESS Astellas CTO Eager to “Democratize” Digital Tools to Boost Productivity
February 21, 2024
-
BUSINESS CureApp Kicks Off Japan PIII Study for NASH Therapeutic App
February 21, 2024
-
BUSINESS Mitsubishi Tanabe Files OD Tablet Form for Canalia in Japan
February 21, 2024
-
REGULATORY Japan to End Public Aid for COVID Drugs at March-End
February 21, 2024
-
REGULATORY AMED Selects 6 VCs for Biotech Startup Funding Project
February 21, 2024
-
REGULATORY MEXT to Ask University Hospitals to Create Reform Plan by June
February 21, 2024
-
REGULATORY Xocova, Astellas’s Gastric Cancer Med Up for PAFSC Review on March 4; Pfizer’s Bispecific, RSV Jab Also on Agenda
February 20, 2024
-
BUSINESS Gilead Japan Ramping Up Sales Force with Trodelvy Now under Review
February 20, 2024
-
BUSINESS Ono, InveniAI Pair Up for AI-Powered Drug Discovery
February 20, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…